

1 **TITLE PAGE**

2

3

4

5 **Metabolic correlates of late midlife cognitive function: findings from the 1946**

6 **British Birth Cohort**

7

8 Rebecca Green^{ab}, Jodie Lord^a, Jin Xu^{ac}, Jane Maddock^d, Min Kim^e, Richard Dobson^{ab},

9 Cristina Legido-Quigley^{ce}, Andrew Wong^d, Marcus Richards^{d*}, Petroula Proitsi^{a*}

10 *equally contributing and co-corresponding authors

11

12 *^aInstitute of Psychology, Psychiatry & Neuroscience, King's College London, London,*

13 *UK.*

14 *^bUK National Institute for Health Research (NIHR) Maudsley Biomedical Research*

15 *Centre, South London and Maudsley Hospital, London.*

16 *^cInstitute of Pharmaceutical Science, King's College London, London, UK.*

17 *^dMRC Unit for Lifelong Health & Ageing at UCL, University College London, London, UK.*

18 *^eSteno Diabetes Center Copenhagen, Gentofte, Denmark.*

19

20

21

22 **NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.**

23 **Abstract**

24 **Background:** Investigating associations between metabolites and late midlife cognitive
25 function could reveal potential markers and mechanistic insights relevant to early dementia.
26 Here, we aimed to identify the metabolic underpinnings of cognitive outcomes in late
27 midlife by exploring and integrating associations of single metabolites, metabolic pathways
28 and networks. We further aimed to untangle the influence of life course factors on these
29 relationships; a previously unexplored avenue using a systems biology approach.

30
31 **Methods and Findings:** Levels of 1019 metabolites were detected by liquid
32 chromatography-mass spectrometry (Metabolon Inc) and quantified at age 60-64 among
33 participants of the British 1946 Birth Cohort (N=1740). Cognitive outcomes were assessed at
34 the same age and 5-9 years later, and included short-term memory (age 60-64, 69 and
35 change), delayed memory (age 60-64), processing speed (age 60-64, 69 and change) and
36 Addenbrooke's Cognitive Examination III (age 69). Using a combination of linear regression
37 analysis, quantitative pathway analysis and weighted gene correlation network analysis, we
38 evaluated relationships between metabolite measures (single-metabolites, pathways and
39 network modules) and cognitive outcomes. Single-metabolite and network analyses were
40 sequentially adjusted for life course factors across four models, including: sex and blood
41 clinic information (model 1); model 1 + BMI and lipid medication (model 2); model 2 +
42 childhood cognition, education and socioeconomic position (model 3); model 3 + smoking,
43 exercise, alcohol intake, blood pressure and diet (model 4).
44 After correcting for multiple tests, we identified 155 metabolites, 10 pathways and 5
45 modules to show relationships with cognitive outcomes. Thirty-five metabolites were
46 influential in their module and identified in single-metabolite analyses. Notably, we report

47 independent relationships between a module comprised of acylcarnitines and processing
48 speed, revealing palmitoylcarnitine (C16) as a key driver of associations (model 4: $\beta = -0.10$,
49 95%CI = -0.15 to -0.052). Two modules demonstrated associations with several cognitive
50 outcomes that were partly explained by life course factors: one enriched in modified
51 nucleosides and amino acids (β range (model 1) = -0.12 to -0.09, attenuation (model 4)=
52 39.2 to 55.5%), and another in vitamin A and C metabolites (β range (model 1) = 0.11 to
53 0.23, attenuation (model 4) = 68.6 to 92.6%). Our other findings, including a module
54 enriched in sphingolipid pathways (β range (model 1) = 0.085 to 0.10, attenuation (model 4)
55 = 87.0 to 116%), were entirely explained by life course factors - particularly childhood
56 cognition and education. The limitations of this study include those commonly seen with
57 population-based cohorts, such as possible residual confounding and generalisability to
58 other populations, as well as a lack of longitudinal metabolite data.

59

60 **Conclusions:** Using a large birth cohort study with information across the life course, we
61 highlighted potential metabolic mechanisms underlying cognitive function in late midlife,
62 suggesting marker candidates and life course relationships for further study.

63

64 **Introduction**

65 Cognitive function in late midlife is indicative of future cognitive trajectories and risk of
66 dementia (1). As dementia is proposed to have a long prodrome, where pathology is
67 accumulating but clinical criteria are not yet met, there presents a promising window to
68 prevent or delay pathology (1). However, a lack of clinically significant symptoms impedes
69 our ability to identify individuals for potential risk-reduction and treatment strategies. As
70 such, our understanding of early disease mechanisms are not well established and no
71 effective disease-modifying treatments are currently used in clinic (2).

72

73 Comprehensive longitudinal studies are required to detect early mechanisms and markers
74 preceding diagnosis, for which studying metabolic correlates may be fruitful. Metabolites,
75 such as fatty acids and amino acids, are low molecular weight compounds derived from
76 cellular metabolism. Lying in closest proximity to the phenotype, they integrate upstream
77 biological systems (e.g. genetics, transcriptomics, proteomics) as well as environmental and
78 lifestyle influences, allowing for a holistic insight into the physiological status of an
79 individual (3). Additionally, they are accessible and potentially modifiable, presenting as
80 promising candidates for markers of pathology (4).

81

82 The biological relevance of metabolic alterations in cognitive function and dementia has
83 been established. Contextually, genome-wide association studies have highlighted
84 enrichment in lipid metabolism pathways in the genetic underpinnings of Alzheimer's
85 disease (AD) (5). Further, many studies have linked metabolites to cognitive function and
86 AD, consistently highlighting species such as sphingolipids, phospholipids, fatty acids,

87 cholesterol and amino acids (6–10), although replication of specific metabolites has proved
88 challenging.

89

90 As metabolites are known to act in concert, investigating many metabolites together can
91 enhance biological interpretation. Systems-level analyses, that are able to capture the
92 complex interactions between metabolites, are required to guide our understanding and
93 identify potential marker candidates for future studies. We recently employed a network
94 approach to explore systems-level changes in AD phenotypes, whereby lipids and proteins
95 were grouped into clusters based on their connectivity, highlighting important pathways in
96 AD pathogenesis (11). A similar methodology was previously applied in the Bogolusa Heart
97 Study to explore the metabolic signature of cognitive function in early midlife (10).

98 However, the molecular correlates of cognitive function relevant to this prodromal window
99 remains unknown. Additionally, given that both metabolites and cognitive function can be
100 influenced by life course factors, it is necessary to evaluate relationships from this context.

101 To our knowledge, life course influences have not yet been explored using a systems
102 approach; it is hoped that this could highlight independent associations as well as suggest
103 relationships for further study - a potentially invaluable layer in untangling early pathology.

104

105 Using the Medical Research Council (MRC) National Survey of Health and Disease (NSHD) -
106 the British 1946 Birth Cohort - we aimed to comprehensively investigate associations
107 between metabolites and cognitive function in late midlife using a life course approach (Fig
108 1). Previously, levels of 233 metabolites and their association with cognitive function were
109 explored in this cohort (6). Since that publication, we now have levels of >1000 metabolites
110 quantified, as well as availability of the Addenbrooke's Cognitive Examination (ACE-III), a

111 comprehensive measure of cognitive state that is also able to screen for cognitive
112 impairment and dementia (12). This provides a good opportunity to delineate pathways and
113 networks associated with cognitive outcomes in late midlife. Integrating the depth and
114 breadth of metabolite-level, pathway-level and network-level approaches, we aimed to
115 identify functionally significant metabolites that may show merit as markers of early
116 pathology. With lifelong information available, we explored the influence of life course
117 factors to untangle these associations further.

MRC 1946 British Birth Cohort Study (n=1740)




Fig 1. Overview of study workflow. Created with BioRender.com

132 **2. Methods and Materials**

133 **2.1 Participants**

134 The MRC NSHD is a nationally representative study, originally consisting of 5362 participants
135 born in England, Scotland and Wales during one week of March in 1946 (13). Twenty-four
136 waves of data have been collected since birth, with the most recent two follow-ups
137 occurring at ages 60-64 (n=2229) and 68-69 years (n=2149). The study sample remains
138 broadly representative of the British-born population at the same age (see (13,14) for
139 further details on participant attrition and representativeness). Participants with full
140 cognition, metabolite and blood clinic data at ages 60-64 were included for this analysis,
141 giving a total sample of 1740 (see S1 Fig for further details on participant flow).

142

143 At age 60-64, ethical approval was obtained from the Greater Manchester Local Research
144 Ethics Committee for the four English sites and the Scotland A Research Ethics Committee.
145 Ethical approval for age 69 was obtained from Queen Square Research Ethics Committee
146 (13/LO/1073) and Scotland A Research Ethics Committee (14/SS/1009). Research was
147 conducted in accordance with the Declaration of Helsinki and all participants provided
148 written informed consent at each wave.

149

150 **2.2 Metabolomics**

151 ***2.2.1. Metabolomics platform***

152 Blood samples were collected during the nurse visit at ages 60-64 (96% fasted, 4% non-
153 fasted). Samples were aliquoted and stored at -80°C.

154

155 Levels of 1401 plasma metabolites were profiled by Metabolon Inc (Durham, NC, USA) using
156 Ultrahigh Performance Liquid Chromatography-Tandem Mass Spectrometry (UPLC-MS/MS).
157 (see S1 Methods for further details). Metabolites were assigned to nine families: lipids
158 (n=494), xenobiotics (n=256), amino acids (n=211), cofactors and vitamins (n=35),
159 nucleotides (n=38), peptides (n=28), carbohydrates (n=22), partially characterised molecules
160 (n=17) and energy (n=9). Additionally, the identity of 291 metabolites were unknown; these
161 metabolites were allocated numbers prefixed by an “X” and were not assigned to any
162 family. Metabolites were further organised into pathways by *Metabolon* based on their
163 proposed biological function informed by the Kyoto Encyclopaedia of Genes and Genomes
164 (KEGG) database.

165

166 **2.2.2. Metabolomics data quality control (QC)**

167 For full details on data QC, see S1 Fig. Briefly, metabolites with >20% of missing data were
168 excluded, leaving 1019 for further analysis. Of the 1019, 193 were metabolites with an
169 unknown identity. Remaining missing data were then taken forward for imputation using k-
170 nearest-neighbours with k=10, as recommended for LC-MS data elsewhere (15). Imputation
171 was carried out using the *impute* package in R (16). Imputed data were then log₁₀
172 transformed to achieve approximately normal distributions.

173

174 **2.3 Cognitive outcomes**

175 Cognitive outcome measures were recorded at two ages, 60-64 and 69. Four aspects of
176 cognitive function were assessed:

177

178

179 *Short-term memory (age 60-64 & 69)*

180 Participants were asked to recall a 15-item word list, developed by the NSHD, after being
181 presented with each word for two seconds. The task was repeated over three trials and the
182 number of accurately recalled words was recorded (max score=45) (17).

183

184 *Processing speed (age 60-64 & 69)*

185 Participants were asked to cross out the letters P and W, randomly distributed on a page
186 containing other letters. One minute was given to complete the task and participants were
187 scored by the number and accuracy of the letters crossed out (max score=600) (17).

188

189 *Delayed memory (age 60-64)*

190 After the processing speed task, an uncued delayed free recall trial was administered (17).

191

192 *Addenbrooke's Cognitive Examination-III (ACE-III) (age 69)*

193 The ACE-III captures cognitive state, and is also a screening tool for cognitive impairment,
194 comprised of five domains: attention and orientation, verbal fluency, memory, language and
195 visuospatial function. Scores represent the total over all domains (max score=100), with
196 lower scores indicating poorer cognitive function (12).

197

198 *Cognitive change*

199 For outcomes with available data at two time points - short-term memory and processing
200 speed - we additionally investigated change in cognition, represented by the standardised
201 residuals of a regression model fit between scores at age 60-64 and 69.

202

203 2.4 Covariables

204 As with previous analyses (6), covariables included the following: sex, blood clinic
205 information (age at blood collection, clinic location and fasting status), body mass index
206 (BMI), lipid medication, childhood cognition, educational attainment, childhood
207 socioeconomic position (SEP), midlife SEP, lifetime smoking, alcohol intake, systolic blood
208 pressure, physical activity and diet.

209

210 *BMI* was calculated using height and weight measures collected during the nurse visit at
211 ages 60-64. At blood collection, the self-reported use of *lipid medication* was recorded and
212 coded as a binary variable reflecting use in the previous 24 hours.

213

214 *Childhood cognition* was represented as a standardised composite score of four tests at age
215 15, including the Heim AH4 (measuring non verbal and verbal ability) (18), the Watts Vernon
216 reading test (measuring reading comprehension) (19), and a test of mathematical ability
217 (19) . *Educational attainment* represented highest level of educational qualification by age
218 26, grouped into three categories: no qualifications, ordinary ('O') level secondary
219 qualifications, or advanced ('A') level secondary and higher. *SEP* was represented in
220 childhood and midlife, coded using the current or last known occupation of the father at age
221 11 and the study member at age 53, respectively. These categories corresponded to those
222 specified in the UK Registrar General's classification: unskilled, partly skilled, skilled manual,
223 skilled nonmanual, intermediate, or professional.

224

225 For lifestyle, *lifetime smoking* was represented by pack years per person between the ages
226 of 20 and 60-64. *Physical activity* was coded as three categories depending on the self-

227 reported frequency of participation in sports, exercises or intense leisure activities in the
228 month prior to the age 60-64 interview: none, 1-4 times per week, or >4 times per week.
229 Where data were present for at least three of four timepoints, average daily *alcohol intake*
230 during midlife was curated from 3-5 day diet diaries at age 36, 43, 53 and 60-64. This
231 measure was then used to assign participants into three categories: no consumption, light-
232 to-moderate consumption, and heavy consumption. *Systolic blood pressure* was
233 represented by the second measurement (mmHg) taken at age 60-64. Finally, the *diet*
234 variable represented adherence scores for the Dietary Approaches to Stop Hypertension
235 (DASH) diet, estimated from 3-5 day diet diaries at age 60-64 (20). The DASH diet is based
236 on a high intake of fruits, vegetables, low-fat dairy products and wholegrains, and a low
237 intake of saturated fat and refined sugars (21). Participants were assigned to sex-specific
238 quintiles, with lower quintiles indicating lower adherence, as described previously (20).
239
240 *APOE* genotype was determined from blood samples collected at age 53 or 69 and analysed
241 as described previously (22). Participants with $\epsilon 2/\epsilon 4$ were excluded (n=46) and *APOE*
242 genotype was coded as homozygous $\epsilon 4$ (n=46), heterozygous $\epsilon 4$ (n=361) or non $\epsilon 4$
243 (n=1068). Genotypes were treated as continuous variables.

244

245 **2.5 Statistical analyses**

246 To optimise power and minimise bias, missing covariate data were imputed using multiple
247 imputation chained equations (*mice*) (23), resulting in fifty imputed datasets (see Table 1 for
248 further details of missing data). All analyses were conducted in R and all results are reported
249 in SD units.

250

251 **2.5.1 Single-metabolite analyses**

252 Predictors and outcomes were z-standardised prior to statistical analysis to allow for direct
253 comparisons. Statistical models evaluated associations between metabolites (predictor) and
254 cognitive test scores (outcome) using multiple linear regression. Regression analyses were
255 performed on each imputed dataset, and estimates were pooled using Rubin's rules. To
256 investigate associations in the context of life course influences, a series of statistical models
257 with sequential adjustment were performed:

258

259 Model 1 (basic covariates): sex, blood clinic, age at blood clinic, fasting status

260 Model 2 (common metabolite confounders): model 1 + BMI, lipid medication

261 Model 3 (social factors and childhood cognition): model 2 + childhood cognition,

262 attainment, SEP (childhood and midlife)

263 Model 4 (lifestyle influences): model 3 + blood pressure, physical activity, alcohol, smoking,

264 diet

265

266 To account for the number of tests performed and correlations between metabolites, a

267 Bonferroni-adjusted significance threshold was set as 0.05 divided by the number of

268 principal components explaining >95% variance in the metabolite data (6); $p < 1.15 \times 10^{-4}$.

269

270 **2.5.2 Pathway analyses**

271 First, metabolon sub-pathway definitions were used to organise metabolites into pathways.

272 Those containing <5 metabolites were excluded, resulting in 53 separate pathways.

273 Metabolite pathway assignment can be found in S1 Table.

274

275 To investigate pathway-level associations, quantitative pathway analysis was performed
276 using an approach reported previously (24). Briefly, we derived pathway z-scores for each
277 participant, representing the standardised expression of metabolites in the pathway. To do
278 this, metabolites were z-standardised, and the mean expression was computed for each
279 pathway. Associations between pathway z-scores and outcomes were then evaluated using
280 linear regression, adjusting for the basic (model 1) covariables listed above.

281

282 A Bonferroni-corrected significance threshold was set at 0.05/53 pathways; $p < 9.43 \times 10^{-4}$.

283

284 **2.5.3 Network analyses**

285 *Network construction*

286 To define metabolic networks, we applied weighted gene coexpression network analysis
287 (WGCNA) to metabolite data, using the WGCNA package in R (25–27). WGCNA is a network
288 analysis approach that organises data into densely connected modules based on pairwise
289 correlations, whereby data in the same module will show high connectivity and those in
290 differing modules, low. Subsequently, the first principal component of the module (module
291 eigenvalue) can be derived and relationships between modules and outcomes can be
292 explored. To infer biological function, overrepresentation analyses are commonly conducted
293 to identify enriched pathways within the module. Additionally, the function of metabolites
294 showing the greatest modular connectivity can be interrogated (25).

295

296 Metabolites were first adjusted for model 1 covariables and the standardised residuals were
297 used for subsequent analysis. Next, the standardised connectivity (Z_k) for each sample was
298 computed to identify outliers, resulting in the exclusion of ten individuals with a Z_k of < -4 .

299 We then derived a pairwise correlation matrix using biweight midcorrelations between all
300 metabolites. From this, a weighted, signed adjacency matrix was constructed by raising
301 correlations to a soft thresholding power of 9, chosen to meet a scale-free topology
302 threshold of ≥ 0.85 while maximising mean connectivity (S3 Fig). Subsequently, the
303 adjacency matrix was transformed into a topological overlap matrix (TOM), representing the
304 network connectivity of metabolites. Metabolites were then hierarchically clustered into a
305 dendrogram using an average linkage method based on their dissimilarity (1-TOM), and the
306 dendrogram was cut using a dynamic hybrid tree cutting algorithm (28) (parameters -
307 $\text{minModuleSize}=20$, $\text{deepSplit}=4$ and $\text{mergeHeight}=0.3$), resulting in 15 metabolite modules.
308 Of these, the 'grey' module, comprised of metabolites that were not assigned to any
309 particular module, was dropped from further analysis. Module eigenvalues were computed
310 for the remaining 14 modules.

311

312 Overrepresentation analyses using the hypergeometric test were performed on modules to
313 identify pathways expressed more than expected by chance. Pathway assignment is detailed
314 in 2.5.2. For all module analyses, a Bonferroni-corrected significance threshold was set at
315 $0.05/14$ modules; $p < 1.14 \times 10^{-3}$.

316

317 *Regression analyses*

318 To evaluate module-outcome relationships in the context of life course influences, modules
319 were subject to the same series of regression models listed in 2.5.1, using z-standardised
320 module eigenvalues as predictors. As modules were curated using the residuals of a
321 regression model fit between metabolites and model 1 covariables, only models 2-4 were
322 performed.

323 *Identification of module hubs*

324 Metabolites that have a high intramodular connectivity (“hub” metabolites) are highly
325 influential in module structure and likely to play central roles in biological function. Highly
326 connected metabolites that also associate with our outcomes thus present as relevant and
327 functionally important candidates for further study.

328

329 To identify hubs, we evaluated associations between metabolites and their assigned module
330 (module membership; kME) using correlations between metabolites and module
331 eigenvalues. Metabolites with a kME of >0.65 were defined as hubs, and filtered for those
332 identified in single-metabolite analyses.

333

334 **2.5.4 Additional analyses**

335 In our preliminary analysis, we investigated associations between all covariables and
336 metabolites, and all covariables and outcomes (adjusting for model 1 covariables) (S2
337 Table). To further investigate whether particular covariables may be driving attenuations,
338 we repeated single-metabolite and module regression analyses, adjusting for model 1
339 covariables and each additional covariable individually (S3 Table and S4 Table).

340

341 For any results significant at the Bonferroni threshold, analyses were rerun additionally
342 adjusting for *APOE* genotype to investigate whether relationships were independent of
343 *APOE* (S5 Table and S6 Table).

344

345 3. Results

346 3.1 Participant characteristics

347 Complete metabolite, cognition and blood clinic data at age 60-64 were available for 1740
348 study participants. Repeated measures at age 69 were present for 1482 (short-term
349 memory) and 1496 (processing speed), and ACE-III scores were present for 1255.

350 Characteristics of participants with complete data for each outcome are shown in Table 1.

351

352 **Table 1. Clinical and demographic characteristics of participants of the MRC 1946 British**

353 **Birth Cohort study**

	Full cognition and metabolite data			
	Age 60-64 (N=1740)	Age 60-64 & processing speed age 69 (N=1496)	Age 60-64 & short-term memory age 69 (N=1482)	Age 60-64 & ACE-III age 69 (N=1255)
Sex				
Male	854 (49.1%)	732 (48.9%)	727 (49.1%)	607 (48.4%)
Female	886 (50.9%)	764 (51.1%)	755 (50.9%)	648 (51.6%)
Fasting blood sample				
Yes	1675 (96.3%)	1446 (96.7%)	1432 (96.6%)	1212 (96.6%)
No	65 (3.7%)	50 (3.3%)	50 (3.4%)	43 (3.4%)
Age				
Mean (SD)	63.20 (1.12)	63.21 (1.12)	63.21 (1.12)	63.22 (1.13)
Father's socioeconomic position, n (%)				
Missing (n)	86	75	75	60
Professional	128 (7.7%)	118 (8.3%)	118 (8.4%)	106 (8.9%)
Intermediate	375 (22.7%)	325 (22.9%)	323 (23.0%)	272 (22.8%)
Nonmanual skilled	293 (17.7%)	264 (18.6%)	261 (18.6%)	217 (18.2%)
Manual skilled	488 (29.5%)	421 (29.6%)	419 (29.8%)	362 (30.3%)
Partly skilled	282 (17.0%)	227 (16.0%)	225 (16.0%)	185 (15.5%)
Unskilled	88 (5.3%)	66 (4.6%)	61 (4.3%)	53 (4.4%)
Socioeconomic position (age 15-53), n (%)				
Missing (n)	10	5	5	3
Professional	139 (8.0%)	125 (8.4%)	124 (8.4%)	104 (8.3%)

Intermediate	724 (41.8%)	641 (43.0%)	638 (43.2%)	542 (43.3%)
Nonmanual skilled	404 (23.4%)	354 (23.7%)	349 (23.6%)	296 (23.6%)
Manual skilled	250 (14.5%)	200 (13.4%)	198 (13.4%)	164 (13.1%)
Partly skilled	165 (9.5%)	132 (8.9%)	130 (8.8%)	114 (9.1%)
Unskilled	48 (2.8%)	39 (2.6%)	38 (2.6%)	32 (2.6%)
Educational attainment (age 26), n (%)				
Missing (n)	90	71	68	55
No qualification	462 (28.0%)	376 (26.4%)	370 (26.2%)	308 (25.7%)
Up to GCSE	477 (28.9%)	409 (28.7%)	406 (28.7%)	354 (29.5%)
A-level or higher	711 (43.1%)	640 (44.9%)	638 (45.1%)	538 (44.8%)
Childhood cognition (age 15) (z-score)				
Missing (n)	252	217	215	177
Mean (SD)	0.00 (1.00)	0.05 (0.99)	0.06 (0.98)	0.07 (0.99)
Lipid medication (age 60-64), n (%)				
No	1318 (75.7%)	1135 (75.9%)	1124 (75.8%)	946 (75.4%)
Yes	422 (24.3%)	361 (24.1%)	358 (24.2%)	309 (24.6%)
BMI (age 60-64) (weight(kg)/height(m)²)				
Missing (n)	2	2	2	2
Mean (SD)	27.76 (4.70)	27.70 (4.56)	27.69 (4.58)	27.61 (4.45)
Physical activity (age 60-64), n (%)				
Missing (n)	48	40	37	32
None	1036 (61.2%)	862 (59.2%)	857 (59.3%)	714 (58.4%)
1-4 times a month	251 (14.8%)	229 (15.7%)	225 (15.6%)	192 (15.7%)
4+ times a month	405 (23.9%)	365 (25.1%)	363 (25.1%)	317 (25.9%)
Lifetime smoking (age 20-64), n (%)				
Missing (n)	347	291	285	243
Mean (SD)	10.79 (15.54)	10.40 (15.28)	10.26 (15.18)	10.51 (15.43)
Lifetime alcohol consumption (age 36-64), n (%)				
Missing (n)	285	226	221	192
No consumption	90 (6.2%)	77 (6.1%)	76 (6.0%)	63 (5.9%)
Light-moderate consumption	1134 (77.9%)	993 (78.2%)	987 (78.3%)	845 (79.5%)
Heavy consumption	231 (15.9%)	200 (15.7%)	198 (15.7%)	155 (14.6%)
Diet quintiles (age 60-64), n (%)				
Missing (n)	246	189	185	166
1	332 (22.2%)	276 (21.1%)	276 (21.3%)	231 (21.2%)
2	302 (20.2%)	266 (20.4%)	263 (20.3%)	209 (19.2%)
3	309 (20.7%)	266 (20.4%)	263 (20.3%)	230 (21.1%)
4	270 (18.1%)	244 (18.7%)	244 (18.8%)	199 (18.3%)

	5	281 (18.8%)	255 (19.5%)	251 (19.4%)	220 (20.2%)
Systolic blood pressure (age 60-64)					
Missing (n)		12	7	6	5
Mean (SD)		136.40 (18.30)	135.78 (18.18)	135.83 (18.20)	135.72 (18.28)
APOE genotype, n (%)					
Missing (n)		217	169	167	146
ε2/ε2		10 (0.7%)	9 (0.7%)	9 (0.7%)	5 (0.5%)
ε2/ε3		177 (11.6%)	152 (11.5%)	151 (11.5%)	119 (10.7%)
ε2/ε4		48 (3.2%)	39 (2.9%)	38 (2.9%)	31 (2.8%)
ε3/ε3		881 (57.8%)	771 (58.1%)	763 (58.0%)	650 (58.6%)
ε3/ε4		361 (23.7%)	316 (23.8%)	314 (23.9%)	270 (24.3%)
ε4/ε4		46 (3.0%)	40 (3.0%)	40 (3.0%)	34 (3.1%)

354





355 3.2 Single-metabolite analyses

356 Overall, we identified 155 metabolites to be associated with a least one cognitive outcome
357 after adjusting for multiple testing: 65 metabolites showed positive relationships, with
358 increased abundance reflecting better cognitive function, and 90 showed negative
359 relationships. No metabolites were associated with cognitive change measures at the
360 Bonferroni threshold; as such, these outcomes will not be further discussed in this section
361 but are presented in S1 Table. Significant metabolites represented all metabolon families
362 but were largely defined as lipids (n=46) and amino acids (n=32). The largest proportion of
363 these metabolites were associated with short-term memory at age 60-64 only, and just over
364 half were associated with more than one outcome (Fig 2). As expected, this indicates some
365 molecular overlap between the cognitive outcomes, although we did observe some unique
366 relationships for processing speed in particular (Fig 2). Full summary statistics are available
367 in S1 Table and visualised in S2 Fig.

368

369
370
371
372
373
374
375
376
377
378
379
380
381
382
383

Metabolite count



384 **Fig 2. (Main) Upset plot depicting the number of metabolites associated with each outcome and combination of outcomes at the adjusted**
385 **threshold, split by metabolite family. Outcomes are shown in the matrix below, with shaded circles demonstrating those represented by**
386 **the bar chart above. Where more than one outcome is indicated, lines further highlight these intersections. Bars are coloured by**
387 **metabolite family and total metabolite counts are displayed on top of each bar, alongside the corresponding percentage proportion of all**
388 **significant metabolites identified across all outcomes. As no metabolites were significant at the adjusted threshold for change outcomes,**
389 **these were not included. (Left) Barplot showing the number of metabolites identified overall for each outcome. Bars are coloured by**
390 **metabolite family and counts are displayed on the top of each bar. This plot was produced using (66). Underlying data are present in S1**
391 **Table. ACE-III = Addenbrooke's Cognitive Examination-III.**

392 Of the 155 metabolites identified across all models, 151 metabolites were identified in
393 model 1. For all non-change outcomes, the metabolites showing the strongest positive
394 effects were cofactors and vitamins involved in vitamin A metabolism; β -cryptoxanthin and
395 carotene diol (1), although this relationship was not significant at the adjusted threshold for
396 processing speed at age 69 ($\beta=0.08$, 95%CI=0.027 to 0.13, $p=3.02 \times 10^{-3}$). The strongest
397 negative relationships were more distinct. Palmitoylcarnitine (C16), a lipid involved in fatty
398 acid (acyl carnitine) metabolism, showed the largest negative association with processing
399 speed at age 60-64. For the other outcomes, several unknown metabolites were revealed:
400 X-24953 (short-term memory (both ages) and delayed memory), X-11372 (ACE-III) and X-
401 21470 (processing speed at age 69).

402

403 After adjusting for BMI and lipid medication (model 2), average effect sizes reduced by 4.1%
404 to 14.8%. However, the bulk of associations were attenuated after adjusting for model 3
405 (parental and own SEP, childhood cognition and own education). Model 3 attenuations were
406 most pronounced for memory outcomes and ACE-III, ranging from 51.3% to 58.4%, and
407 milder for processing speed (age 69 - 10.7%, age 60-64 - 31.5%). Subsequently, seven
408 metabolites were significant at the adjusted threshold, including one previously nominal
409 association – margaroylcarnitine (C17)*.

410

411 In the fully adjusted model (model 4), four metabolites remained significant at the adjusted
412 threshold: X – 17676 (short-term memory and delayed memory at age 60-64), C16
413 (processing speed at age 60-64), C17 (processing speed at age 60-64) and imidazole
414 propionate (short-term memory age 69) (see Table 2 for final results and overall change
415 from models 1 to 4). Eighty metabolites remained nominally significant. For processing

416 speed at age 60-64, model 4 adjustments resulted in a modest decrease in effect magnitude
417 (19.7%), with milder reductions for the other outcomes (3.2-7.9%). Of note, we did not
418 identify any significant changes in our results following adjustment for APOE (S5 Table).

419

420 **Table 2. Biological family, pathway and key results for significant metabolites in the final**
421 **model (Model 4)**

Metabolite	Family	Pathway	Model 1	Model 4	β change from Model 1 to 4 (%)
X – 17676	Unknown	Unknown	STM (69y) $\beta = -0.14$ 95%CI = -0.19 to -0.089 $p = 5.29 \times 10^{-8}$ DM (60-64y) $\beta = -0.11$ 95%CI = -0.15 to -0.061 $p = 5.45 \times 10^{-6}$	STM (69y) $\beta = -0.11$ 95%CI = -0.15 to -0.06 $p = 4.84 \times 10^{-6}$ DM (60-64y) $\beta = -0.082$ 95%CI = -0.12 to -0.04 $p = 1.11 \times 10^{-4}$	STM (69y) β change = -24.69% DM (60-64y) β change = -23.56%
Palmitoylcarnitine (C16)	Lipid	Fatty Acid Metabolism (Acyl Carnitine)	PS (60-64y) $\beta = -0.11$ 95%CI = -0.16 to -0.062 $p = 9.19 \times 10^{-6}$	PS (60-64y) $\beta = -0.10$ 95%CI = -0.15 to -0.052 $p = 5.99 \times 10^{-5}$	PS (60-64y) β change = -9.49%
Margaroylcarnitine (C17)*	Lipid	Fatty Acid Metabolism (Acyl Carnitine)	PS (60-64y) $\beta = -0.067$ 95%CI = -0.11 to 0.020 $p = 5.40 \times 10^{-3}$	PS (60-64y) $\beta = -0.095$ 95%CI = -0.14 to -0.048 $p = 8.33 \times 10^{-5}$	PS (60-64y) β change = +40.75%
Imidazole propionate	Amino Acid	Histidine Metabolism	STM (69y) $\beta = -0.14$ 95%CI = -0.19 to -0.091 $p = 4.98 \times 10^{-8}$	STM (69y) $\beta = -0.094$ 95%CI = -0.14 to -0.048 $p = 7.91 \times 10^{-5}$	STM (69y) β change = -33.48%

422 *STM = short-term memory, DM = delayed memory, PS = processing speed.*

423

424

425 3.3 Pathway analyses

426 Next, we characterised potential pathway involvement. Our results are presented in Fig 3
427 and S7 Table. No pathway was significant at the adjusted threshold for processing speed at
428 age 69, nor for the cognitive change measures, although some nominal associations were
429 observed.

430

431 Pathways significant at the adjusted threshold ($p < 9.43 \times 10^{-4}$) are discussed hereafter.


432 Briefly, the Vitamin A metabolism pathway was positively associated with all other
433 outcomes. Ascorbate and aldarate metabolism, another pathway related to cofactors and
434 vitamins metabolism, was also positively associated with short-term memory at both time
435 points.

436

437 Negative relationships were observed between the purine metabolism (adenine containing)
438 pathway and short-term memory, delayed memory and ACE-III. Short-term memory
439 displayed some unique relationships at the adjusted threshold, although these pathways did
440 show nominal relationships with at least two of the other outcomes. At age 60-64, five
441 pathways (methionine; cysteine, SAM and taurine metabolism; urea cycle (arginine and
442 proline metabolism); purine metabolism ((hypo)xanthine/inosine); fatty acid (monohydroxy
443 and endocannabinoid) showed additional negative associations. At age 69, two pathways
444 (pyrimidine metabolism (uracil); gamma-glutamyl amino acid) were additionally associated.

445

It is made available under a [CC-BY-NC-ND 4.0 International license](https://creativecommons.org/licenses/by-nc-nd/4.0/).



465 **Fig 3. Plot representing pathway-outcome associations, organised by metabolite family.**

466 **Bonferroni-significant pathways ($p < 9.43 \times 10^{-4}$) are represented by a solid fill and nominal**
 467 **metabolites by a faint fill ($p < 0.05$). Underlying data are present in S7 Table.**

468 *Carb = carbohydrates, Cof & Vit = cofactors and vitamins, PCM = partially characterized*


469 *molecules, Pep = peptides.*


470 3.5 Network analyses

471 We next adopted a network approach, WGCNA, to explore relationships between groups of
 472 densely connected metabolites and cognitive outcomes. We identified 14 modules
 473 comprised of between 22 to 192 metabolites, with regression analyses revealing five of
 474 these to be associated with cognitive outcomes at the adjusted threshold ($p < 1.14 \times 10^{-3}$):
 475 two showing positive associations and three showing negative associations (Fig 4). All but
 476 one module were enriched in a biological pathway (Fig 4 and S8 Table), and no results were
 477 significant at the Bonferroni threshold for cognitive change measures. As with single-
 478 metabolite analyses, we further adjusted for life course factors, detailed below. Key results
 479 are presented in Fig 5 and full summary statistics are available in S9 Table.

480


A





492 **Fig 4. A) Module dendrogram and heatmap of module-outcome associations. Effect sizes**
 493 **and unadjusted p-values are presented in the tiles and significant associations**
 494 **($p < 1.14 \times 10^{-3}$) are highlighted in bold. For clarity purposes, only outcomes demonstrating a**
 495 **Bonferroni-significant result are shown. B) Overrepresented pathways for each module.**
 496 **Only pathways significant at the adjusted threshold ($p < 9.43 \times 10^{-4}$) are shown. P-values are**
 497 **unadjusted. Underlying data are present in S8 Table and S9 Table.**

498 *STM = short-term memory, DM = delayed memory, ACE-III = Addenbrooke's Cognitive*
 499 *Examination-III, PS = processing speed.*



514 **Fig 5. Forest plot showing associations between modules and outcomes in models 1-4. Bonferroni-significant modules ($p < 1.14 \times 10^{-3}$) are**
 515 **represented by a solid fill, nominal modules ($p < 0.05$) by a fainter fill and modules that are not significant at either threshold are**
 516 **represented by the faintest fill. For clarity purposes, only outcomes demonstrating a Bonferroni-significant result are shown. Underlying**
 517 **data are present in S9 Table.**

518 **3.5.1 Positive relationships were seen for yellow and cyan modules**

519 The cyan module – enriched in ascorbate and aldarate metabolism, vitamin A metabolism
520 and food/plant consumption – exhibited the strongest positive relationship with all but one
521 of the cognitive outcomes. This effect was significant at the adjusted threshold for most
522 outcomes, with the exception of processing speed at age 69 ($p=0.024$) and change measures
523 (short-term memory – $p=8.03 \times 10^{-3}$, processing speed – $p=0.81$). Adjusting for BMI and lipid
524 medication (model 2) slightly attenuated relationships (5.4-14.1%), with model 3
525 adjustments again showing the greatest reductions (42.2-72.5%). As a result, short-term
526 memory at age 60-64 and 69 remained significant at the adjusted threshold, but all other
527 associations were lost. Our additional analysis indicated that all model 3 covariables were
528 able to reduce associations, with childhood cognition and education resulting in the biggest
529 attenuations (S4 Table). After adjusting for lifestyle factors (model 4), effect sizes reduced
530 by a further 36.1% for processing speed at age 60-64, with smaller reductions (8.4-9.3%)
531 observed for the other outcomes (Fig 5). Subsequently, short-term memory was no longer
532 significant at the adjusted threshold, but did remain nominally associated (age 60-64 -
533 $\beta=0.068$, 95%CI =0.022 to 0.11, $p=4.10 \times 10^{-3}$; age 69 - $\beta=0.066$, 95%CI=0.013 to 0.12,
534 $p=0.015$). Overall attenuations ranged from 68.6-92.6%.

535
536 We similarly found the yellow module – enriched in sphingolipid metabolism and other lipid
537 pathways – to display positive associations with ACE-III, delayed memory and short-term
538 memory at age 60-64 at the adjusted threshold. We saw modest to large effect size
539 reductions (18.1-34.2%) in model 2, with all relationships lost after adjusting for multiple
540 tests. Model 3 adjustments resulted in substantial further effect reductions (66.3-84.8%),
541 again with childhood cognition and education resulting in the biggest attenuations (S4

542 Table). Minimal additional changes were seen in model 4, and overall attenuations ranged
543 from 87.0-116%.

544

545 ***3.5.1 Negative relationships were seen for turquoise, purple and brown modules***

546 The turquoise module - enriched in several amino acid metabolism pathways - displayed
547 negative associations with ACE-III, short-term memory (both time points) and delayed
548 memory. Module-outcome relationships were most sensitive to model 2 adjustments,
549 decreasing by 20.9-30%. As such, associations were lost at the adjusted threshold for ACE-III
550 and delayed memory, but remained nominally significant. A further attenuation of 11.7-
551 27.1% was observed in model 3, before changing by a small margin (0.95-5.2%) in model 4.
552 No associations passed multiple testing correction in the final model, but all relationships
553 remained at the nominal threshold: standardised betas ranged from -0.068 to -0.046; and p
554 values from 0.0060 to 0.043. Overall attenuations ranged from 39.2-55.5%.

555

556 Negative associations were also identified between the purple module - enriched in fatty
557 acid (acyl carnitine) metabolism – and processing speed at age 69. This relationship
558 remained significant and relatively stable across all stages of covariable adjustment,
559 demonstrating an effect size reduction of 6% overall and a final effect size of $\beta=-0.080$
560 (95%CI=-0.13 to -0.029, $p=2.33 \times 10^{-3}$). Similar effect directions were detected for both
561 processing speed at age 60-64 and change in processing speed throughout, although this
562 was nominally significant (model 4: age 60-64 - $\beta=-0.053$, 95%CI=-0.10 to -0.0061, $p=0.027$;
563 change - $\beta=-0.065$, 95%CI=-0.12 to -0.012, $p=0.016$).

564

565 Finally, we identified the brown module - enriched in diacylglycerol and
566 phosphatidylethanolamine (PE) pathways - to be negatively associated with short-term
567 memory at age 60-64. In model 2, associations were largely reduced (63.3%) and no longer
568 significant; this appeared to be mainly driven by BMI (S4 Table). Subsequent model
569 adjustments resulted in full attenuation.

570

571 Results were largely unchanged after adjusting for APOE, with all previously significant
572 modules remaining significant at the nominal or Bonferroni threshold in the basic model. In
573 the final model we observed a similar pattern, with the exception of the turquoise module
574 and delayed memory which was no longer significant at the nominal threshold (S6 Table).

575


576 **3.5.3 Hub metabolites**

577 To highlight possible key drivers, we focused in on metabolites showing a high intramodular
578 connectivity (kME >0.65) and integrated this with our single-metabolite results. Thirty-five
579 of the 155 metabolites identified in single-metabolite analyses were revealed to be hubs
580 (Fig 6 and S1 Table). Hub metabolites belonged to 10 modules and represented various
581 pathways, including eight of the 10 identified in our pathway analyses at the adjusted
582 threshold: gamma-glutamyl amino acid; methionine, cysteine, SAM and taurine metabolism;
583 purine metabolism, (hypo)xanthine/inosine containing; purine metabolism, adenine
584 containing; pyrimidine metabolism, uracil containing; ascorbate and aldarate metabolism;
585 vitamin A metabolism; and fatty acid (monohydroxy). In model 4, one hub – C16 – was
586 significant at the adjusted threshold and 17 were nominally significant.

587

588

It is made available under a [CC-BY-NC-ND 4.0 International license](https://creativecommons.org/licenses/by-nc-nd/4.0/).



605 **Fig 6. Heatmap showing trends of associations between hub metabolites and cognitive**
 606 **outcomes in models 1-4. Panels on the right indicate the pathways (text) and modules**
 607 **(colour) represented by metabolites. Pathways are suffixed with an asterisk if they were**
 608 **previously identified in our pathway analyses (** = $p < 9.43 \times 10^{-4}$, * = $p < 0.05$).**
 609 **Bonferroni-significant metabolites ($p < 1.15 \times 10^{-4}$) are represented by a solid fill, nominal**
 610 **metabolites by a faint fill ($p < 0.05$), and non-significant metabolites by no fill ($p > 0.05$). Tiles**
 611 **are coloured by effect direction and effect sizes are noted in the centre. For clarity**

612 **purposes, only outcomes demonstrating a Bonferroni-significant result are shown.**

613 **Underlying data are present in S1 Table.**

614 *STM = short-term memory, PS = processing speed, DM = delayed memory, ACE-III = Addenbrooke's*

615 *Cognitive Examination-III.*

616

617 **4. Discussion**

618 Using the British 1946 Birth Cohort, we systematically evaluated the metabolic correlates of
619 cognitive function in late midlife while untangling the influence of life course factors. We
620 identified 155 metabolites, ten metabolic pathways and five modules of coexpressed
621 metabolites to show associations with cognitive outcomes. A large proportion of our results
622 converged using multiple analytical approaches, adding weight to their involvement in
623 cognitive outcomes in late midlife. Integrating these, 35 hub metabolites were revealed to
624 show potential as candidates for further study. Some relationships were independent of life
625 course influences, providing insight into unique metabolic mechanisms underlying cognitive
626 outcomes. However, consistent with our previous analyses in the MRC 1946 (6), as well as a
627 previous lipidomics study in the Lothian Birth Cohort (29), many were sensitive to social
628 factors and childhood cognition, suggesting important considerations for future studies.

629
630 Our most robust finding was for increased serum acylcarnitines and worse processing
631 speed. The purple module - enriched in medium and long chain acylcarnitines - showed
632 negative relationships that were independent of life course factors. Interestingly,
633 associations were strongest for processing speed 5-9 years later (age 69), although similar
634 patterns were observed for both baseline (age 60-64) and change at the nominal threshold.
635 These relationships were specific to processing speed, indicating a possible mechanism
636 unique to this outcome; our pathway analysis was largely in support of this. One metabolite,
637 C16 (a long chain acylcarnitine) appeared to be a key driver in these associations, suggesting
638 a potential candidate and pathway for further investigation.

639

640 Biologically, medium and long chain acylcarnitines are derivatives of fatty acid metabolism
641 and known to be pivotal in mitochondrial fatty acid oxidation (30). Increased abundances in
642 serum have thus been regarded as proxies for mitochondrial dysfunction and impairments
643 in subsequent energy production (30). More specifically, C16 has also been linked to the
644 induction and regulation of apoptotic events (31). Both apoptosis and mitochondrial
645 dysfunction have been implicated in neurodegeneration, indicating a plausible biological
646 mechanism behind our observations (32,33).

647

648 Perturbations in acylcarnitine levels have been reported in early cognitive impairments and
649 AD (7,34,35). Serum levels have also been linked to other traits, such as insulin
650 resistance(36,37), obesity (37) and cardiovascular disease (38), similarly demonstrating
651 independent effects from known risk factors. Although these factors show influence on
652 cognitive function, our associations remained following adjustment for several related
653 factors such as blood pressure, BMI and lipid medication. Taken together, this presents the
654 possibility that alterations may reflect metabolic dysfunction, conferring vulnerability to
655 adverse health outcomes including decline in processing speed. Future studies will seek to
656 further establish whether these changes lie on the causal pathway.

657

658 We also discovered a module comprised of nucleotides and amino acids, turquoise, to
659 demonstrate negative associations with short-term memory, delayed memory and ACE-III.
660 As the largest module, it was enriched in several pathways, including three which were
661 brought to our attention in pathway analyses (histidine metabolism; methionine, cysteine,
662 SAM and taurine metabolism; gamma-glutamyl amino acid metabolism). Purine and
663 pyrimidine metabolism pathways were additionally represented by module hubs and

664 further corroborated by pathway analyses. Relationships remained nominally significant
665 after adjusting for life course factors, reducing by 39.2-55% overall.

666

667 The top driver of the module was 2,3-dihydroxy-5-methylthio-4-pentenoic acid
668 (DMTPA), belonging to the methionine, cysteine, SAM and taurine metabolism pathway.

669 Additional module hubs were amino acids and nucleosides that were unified by the

670 presence of modifications. Included in these were several markers of RNA turnover, a

671 gamma-glutamyl amino acid and a marker of oxidative stress (39–41). The methionine,

672 cysteine, SAM and taurine metabolism pathway has a key role in post-transcriptional and

673 post-translational modifications, including the sourcing of methyl and aminocarboxypropyl

674 groups demonstrated in some module hubs (42,43), indicating plausible relationships linking

675 these metabolites.

676

677 With key roles in the expression, function and stability of molecules, RNA and amino acid

678 modifications are able to regulate a multitude of biological and pathological processes,

679 although precise mechanisms remain elusive (44,45). Aberrant patterns are thought to

680 underly a host of chronic diseases (44), and are gaining attention in the field of

681 neurodegeneration, with a recent paper reporting differential expression of RNA

682 modifications in the post mortem brains of dementia patients (46). Interestingly, the many

683 module hubs have been consistently reported together in adverse outcomes, including

684 hypertension (47), chronic kidney disease (48,49), inflammation (50) and mortality (51). This

685 signature has been previously shown to be relevant to cognitive function as well; in the

686 Bogalusa heart study, a module was curated with similar top drivers, showing associations

687 with cognitive outcomes in midlife (10). For the first time, we have reported such an

688 association in the context of late midlife cognitive outcomes, finding observational
689 relationships with ACE-III, as well as with memory more generally.
690
691 The widespread associations of these module hubs together in adverse outcomes presents
692 the possibility that they could reflect global disease burden or converging pathological
693 mechanisms. A previous study hypothesised that increased levels of modified amino acids
694 may represent an accelerated ageing phenotype and suggested modified nucleotides to be a
695 marker of tissue breakdown and oxidative stress (52), which we know to be implicated in
696 decline in cognitive function (53). Lending some support for this, life course factors related
697 to these processes, such as BMI and smoking, were associated with the module. However,
698 none were able to suitably explain relationships, suggesting that our findings could be
699 capturing converging mechanisms that are independent of these factors.

700

701 We reported relationships between sphingolipids and improved cognitive function which
702 were entirely explained by life course factors, particularly childhood cognition and
703 education. Positive associations were observed between the yellow module - enriched in
704 several pathways related to sphingolipid metabolism - and the ACE-III, as well as short-term
705 and delayed memory at age 60-64. Nominal associations were also recorded for sphingolipid
706 pathways and these outcomes. Module associations exhibited major reductions in model 3,
707 and attenuated by 87-116% overall, with no hubs remaining associated with cognitive
708 outcomes; this was surprising given the attention sphingolipid metabolism has received in
709 the neurodegeneration field. We saw similar patterns for the brown module - enriched in
710 diacylglycerol and PE – for which relationships attenuated in model 2, although effects were
711 relatively small and only reported for short-term memory at age 60-64.

712 Previous research has implicated disturbances in sphingolipid balance in cognitive
713 development (54,55), function (55), ageing (55,56) and AD (57). Sphingolipids are a lipid
714 family comprised of sphingomyelins, ceramides and glycosphingolipids, and are present in
715 large quantities in the CNS (57). Forming important components of cell membranes, they
716 are highly dynamic and display crucial roles in cognitive development and function (55). In
717 this regard, all yellow module hubs were sphingomyelin species - the most abundant
718 sphingolipid with pivotal roles in myelin integrity and function (54). However, despite
719 findings highlighting altered sphingolipid balance in cognitive decline and AD, replication of
720 specific sphingolipids has proved challenging. This could be due to their delicate balance and
721 dynamicity, or perhaps due to fluctuations as a function of pathology, with differing
722 relationships observed throughout the disease course. Alternatively, inconsistencies in
723 incorporating life course factors in analytical models could be a contributor.

724

725 Given observational findings linking sphingolipids and cognitive function at several stages of
726 the life course, there exists several possibilities of the loss of relationships after model 3
727 adjustments, and particularly for childhood cognition and education. Attenuations following
728 adjustment for childhood cognition suggests confounding through reverse causation. In the
729 case of education, this may influence levels through other exposures, resulting in spurious
730 associations between late midlife sphingolipid levels and late midlife cognitive outcomes.
731 However, due to a lack of longitudinal metabolite data, we cannot rule out the possibility
732 that later life sphingolipid levels may be a proxy for those of earlier life. In this regard,
733 childhood cognition and education could be mediators of early life sphingolipid levels and
734 later life cognitive function; or perhaps they may be linked by common genetic or
735 environmental causes. Future studies aiming to unravel the precise nature of these life

736 course relationships will be crucial in understanding the importance of sphingolipids in
737 cognitive outcomes in later life. Nevertheless, our findings suggest that these factors need
738 to be carefully considered in future investigations into metabolic underpinnings of cognitive
739 function and decline.

740

741 Finally, a module enriched in vitamin A and C metabolites, cyan, showed positive
742 associations with most cognitive outcomes. Notably, our model 1 results suggested a
743 ubiquitous positive role of vitamin A metabolites for cognitive outcomes, with the cyan
744 module, vitamin A metabolism pathway and metabolites (carotenoids) contained within this
745 pathway displaying the largest overall effects across all stages of analysis. Despite large
746 effect sizes, associations were sensitive to adjustment for life course factors, namely
747 childhood cognition and social factors. In the final model, relationships were largely
748 explained for processing speed and ACE-III, displaying attenuations of >90%. Reductions
749 were also seen for short-term memory at both time points (68.6 and 71.1%), but
750 associations remained at the nominal threshold.

751

752 Oxidative stress is thought to be involved in the pathogenesis of neurodegenerative
753 diseases and is characterised by an overabundance of reactive oxygen species, initiating a
754 host of deleterious effects (58). Antioxidants, including vitamin C metabolites and
755 carotenoids, may inhibit such processes through scavenging of these species (59). Due to
756 this, their involvement in ageing, cognitive decline and AD has been discussed, and all five of
757 the present hubs have previously shown apparent protective effects in small studies
758 investigating cognitive impairments (60–62). Nevertheless, contributions are debated, with
759 epidemiological studies showing conflicting results (63,64).

760 While generally acquired through food consumption, it is unclear whether our findings
761 reflect increased intake or bioavailability, or accumulate consequentially as a marker of
762 reduced antioxidant requirements. In a previous study exploring metabolite markers of
763 healthy nutritional patterns, three of the module hubs (glycerate, stachydrine and oxalate)
764 were highly correlated with the intake of foods rich in antioxidants and minerals (65).
765 Although we identified strong relationships between the module and dietary scores, diet
766 was not able to suitably explain observed relationships. As the cyan module exhibited
767 significant associations with all covariables, it is plausible that it could be capturing a more
768 pervasive mechanism such as oxidative stress and subsequent antioxidant requirements.
769
770 It was interesting to note that, following life course adjustment, relationships were largely
771 explained for processing speed and ACE-III, but nominal residual relationships remained for
772 short-term memory at both time points, with age 60-64 just shy of the adjusted threshold.
773 Although these relationships still showed marked attenuations, this indicates that there may
774 be some independent effects specific to short-term memory at these ages. As discussed
775 with previously, attenuations suggest confounding by childhood cognition and social factors,
776 or may reflect relationships we are not able to capture without longitudinal metabolite
777 data. Further research is required to understand these relationships in greater depth.
778
779 Findings should be considered in light of several strengths and limitations. First, our study
780 incorporated a variety of known confounders and our results converged through a variety of
781 methodological techniques. Using a sequential analytical design further allowed for greater
782 insight into influencing life course factors. However, our results may still be subject to
783 residual confounding. We additionally do not have longitudinal metabolomics data,

784 precluding investigation into lifelong relationships and directionality. Our next step will be
785 to interrogate the causal nature of associations highlighted in this study through methods
786 such as Mendelian Randomisation, as well as to externally replicate our work. Next,
787 cognitive change measures were curated from data collected at two time points within a
788 small time window, which could explain the lack of relationships observed; it will be
789 interesting to investigate this in future waves. Further, change measures were represented
790 by residualised change scores which can be subject to bias and our findings should be
791 interpreted with this in caution. The NSHD is a large nationally recruited sample with a
792 narrow age range, thus overcoming confounding by age or recruitment strategy. With a
793 large array of available measures, we were able to investigate prospective measures
794 collected from birth as well as comprehensive measures of cognitive function, including the
795 ACE-III. Looking at several domains of cognition further allowed us to identify more specific
796 relationships that may otherwise have been missed. As seen with many cohort studies,
797 individuals remaining in the study at this stage were generally of higher cognitive ability in
798 childhood and more socially advantaged compared to the sample initially recruited at birth.
799 Additionally, the study sample was ethnically homogenous. For generalisation, it is
800 paramount to replicate this work in more diverse populations. Finally, we used a
801 comprehensive metabolomics platform to acquire untargeted metabolite data, which
802 provided unbiased and granular metabolite profiles for our analyses. Due to this, levels of
803 metabolites with unknown identities were captured; module analysis yielded some insight
804 into a broad identity and function, but precise characterisation is not yet available.
805
806 In summary, we conducted one of the largest LC-MS studies to date on cognitive outcomes
807 in late midlife, and are the first to systematically evaluate associations in the context of life

808 course factors. We integrated metabolites, pathways and networks, offering biological
809 interpretation while retaining granularity, illuminating important pathways and drivers of
810 cognitive outcomes in late midlife. Our results illustrate the importance of incorporating life
811 course influences, with many relationships largely explained by childhood cognition and
812 education; our further studies will aim to unpick this. Finally, we identified several
813 metabolites (e.g. C16) that were both pivotal to module function and associated with our
814 outcomes, presenting as potential marker candidates for additional study.
815

816 **Acknowledgements**

817 PP is funded by Alzheimer’s Research UK and RG by the National Institute for Health
818 Research (NIHR) Biomedical Research Centre.

819

820 This paper represents independent research part-funded by the National Institute for Health

821 Research (NIHR) Biomedical Research Centre at South London and Maudsley NHS

822 Foundation Trust and King’s College London. The views expressed are those of the author(s)

823 and not necessarily those of the NHS, the NIHR or the Department of Health and Social Care.

824 This work was further supported by the UK Medical Research Council which provides core

825 funding for the MRC National Survey of Health and Development.

826

827 We thank NSHD study members for their lifelong participation and past and present

828 members of the NSHD study team who helped to collect the data. We also thank ACE

829 Mobile for providing a customised version of the ACE-III for NSHD.

830

831 **Competing interests**

832 The authors declare no competing interests.

833

834 **Correspondence**

835 Correspondence to Petroula Proitsi & Marcus Richards.

836

837 **References**

- 838 1. Livingston G, Huntley J, Sommerlad A, Ames D, Ballard C, Banerjee S, et al. Dementia
839 prevention, intervention, and care: 2020 report of the Lancet Commission. *Lancet*.
840 2020;396(10248):413–46.
- 841 2. Cummings J. Lessons Learned from Alzheimer Disease: Clinical Trials with Negative
842 Outcomes. *Clin Transl Sci*. 2018;11(2):147–52.
- 843 3. Wishart DS. Emerging applications of metabolomics in drug discovery and precision
844 medicine. *Nat Rev Drug Discov*. 2016;15(7):473.
- 845 4. Beebe K, Kennedy AD. Sharpening Precision Medicine by a Thorough Interrogation of
846 Metabolic Individuality. *Comput Struct Biotechnol J*. 2016;14:97–105.
- 847 5. Kunkle BW, Grenier-Boley B, Sims R, Bis JC, Damotte V, Naj AC, et al. Genetic meta-
848 analysis of diagnosed Alzheimer’s disease identifies new risk loci and implicates A β ,
849 tau, immunity and lipid processing. *Nat Genet*. 2019;51(3):414–30.
- 850 6. Proitsi P, Kuh D, Wong A, Maddock J, Bendayan R, Wulaningsih W, et al. Lifetime
851 cognition and late midlife blood metabolites: findings from a British birth cohort.
852 *Transl Psychiatry*. 2018;8(1):203.
- 853 7. Toledo JB, Arnold M, Kastenmüller G, Chang R, Baillie RA, Han X, et al. Metabolic
854 network failures in Alzheimer’s disease: A biochemical road map. *Alzheimers Dement*.
855 2017;13(9):965–84.
- 856 8. Jiang Y, Zhu Z, Shi J, An Y, Zhang K, Wang Y, et al. Metabolomics in the Development
857 and Progression of Dementia: A Systematic Review. *Front Neurosci*. 2019;13:343.
- 858 9. van der Lee SJ, Teunissen CE, Pool R, Shipley MJ, Teumer A, Chouraki V, et al.
859 Circulating metabolites and general cognitive ability and dementia: Evidence from 11
860 cohort studies. *Alzheimer’s Dement*. 2018;14(6):707–22.

- 861 10. Shi M, Bazzano LA, He J, Gu X, Li C, Li S, et al. Novel serum metabolites associate with
862 cognition phenotypes among Bogalusa Heart Study participants. *Aging (Albany NY)*.
863 2019;11(14):5124–39.
- 864 11. Xu J, Bankov G, Kim M, Wretlind A, Lord J, Green R, et al. Integrated lipidomics and
865 proteomics network analysis highlights lipid and immunity pathways associated with
866 Alzheimer’s disease. *Transl Neurodegener*. 2020;9(1):36.
- 867 12. Hsieh S, Schubert S, Hoon C, Mioshi E, Hodges JR. Validation of the Addenbrooke’s
868 Cognitive Examination III in Frontotemporal Dementia and Alzheimer’s Disease.
869 *Dement Geriatr Cogn Disord*. 2013;36(3–4):242–50.
- 870 13. Stafford M, Black S, Shah I, Hardy R, Pierce M, Richards M, et al. Using a birth cohort
871 to study ageing: representativeness and response rates in the National Survey of
872 Health and Development. *Eur J Ageing*. 2013;10(2):145–57.
- 873 14. Kuh D, Wong A, Shah I, Moore A, Popham M, Curran P, et al. The MRC National
874 Survey of Health and Development reaches age 70: maintaining participation at older
875 ages in a birth cohort study. *Eur J Epidemiol*. 2016;31(11):1135–47.
- 876 15. Do KT, Wahl S, Raffler J, Molnos S, Laimighofer M, Adamski J, et al. Characterization
877 of missing values in untargeted MS-based metabolomics data and evaluation of
878 missing data handling strategies. *Metabolomic*. 2018;14(10):128.
- 879 16. Hastie T, Tibshirani R, Narasimhan B, Gilbert C. impute: Imputation for microarray
880 data [software]. 2019.
- 881 17. James S-N, Davis D, O’Hare C, Sharma N, John A, Gaysina D, et al. Lifetime affective
882 problems and later-life cognitive state: Over 50 years of follow-up in a British birth
883 cohort study. *J Affect Disord*. 2018;241:348–55.
- 884 18. Heim AW. *Manual for the AH4 Group Test of General Intelligence*. Windsor: NFER.

- 885 1970.
- 886 19. Pigeon DA, Douglas JWB, Ross JM, Simpson HR. Details of the fifteen years tests. All
887 our Future. London: Davies. 1968;11.
- 888 20. Maddock J, Ziauddeen N, Ambrosini GL, Wong A, Hardy R, Ray S. Adherence to a
889 Dietary Approaches to Stop Hypertension (DASH)-type diet over the life course and
890 associated vascular function: a study based on the MRC 1946 British birth cohort. Br J
891 Nutr. 2018;119(5):581–9.
- 892 21. Appel LJ, Moore TJ, Obarzanek E, Vollmer WM, Svetkey LP, Sacks FM, et al. A clinical
893 trial of the effects of dietary patterns on blood pressure. DASH Collaborative
894 Research Group. N Engl J Med. 1997;336(16):1117–24.
- 895 22. Richards M, James S-N, Sizer A, Sharma N, Rawle M, Davis DHJ, et al. Identifying the
896 lifetime cognitive and socioeconomic antecedents of cognitive state: seven decades
897 of follow-up in a British birth cohort study. BMJ Open. 2019;9(4):e024404.
- 898 23. van Buuren S, Groothuis-Oudshoorn K. mice: Multivariate Imputation by Chained
899 Equations in R. J Stat Software; 2011;45(3):1-67.
- 900 24. Krumsiek J, Mittelstrass K, Do KT, Stückler F, Ried J, Adamski J, et al. Gender-specific
901 pathway differences in the human serum metabolome. Metabolomics.
902 2015;11(6):1815–33.
- 903 25. Zhang B, Horvath S. A general framework for weighted gene co-expression network
904 analysis. Stat Appl Genet Mol Biol. 2005;4(1).
- 905 26. Langfelder P, Horvath S. WGCNA: an R package for weighted correlation network
906 analysis. BMC Bioinformatics. 2008;9(1):559.
- 907 27. Langfelder P, Horvath S. Fast R functions for robust correlations and hierarchical
908 clustering. J Stat Softw. 2012;46(11).

- 909 28. Langfelder P, Zhang B, Horvath S. Defining clusters from a hierarchical cluster tree:
910 the Dynamic Tree Cut package for R. *Bioinformatics*. 2008;24(5):719–20.
- 911 29. Corley J, Starr JM, Deary IJ. Serum cholesterol and cognitive functions: the Lothian
912 Birth Cohort 1936. *Int Psychogeriatrics*. 2015;27(3):439–53.
- 913 30. McCoin CS, Knotts TA, Adams SH. Acylcarnitines—old actors auditioning for new roles
914 in metabolic physiology. *Nat Rev Endocrinol*. 2015;11(10):617.
- 915 31. Mutomba M, Yuan H, Konyavko M, Adachi S, Yokoyama C, McGarry JD, et al.
916 Regulation of the activity of caspases by L-carnitine and palmitoylcarnitine. *FEBS Lett*.
917 2000;478:19–25.
- 918 32. Jones LL, McDonald DA, Borum PR. Acylcarnitines: Role in brain. *Prog Lipid Res*.
919 2010;49(1):61–75.
- 920 33. Shimohama S. Apoptosis in Alzheimer’s disease—an update. *Apoptosis*. 2000;5(1):9–
921 16.
- 922 34. van der Velpen V, Teav T, Gallart-Ayala H, Mehl F, Konz I, Clark C, et al. Systemic and
923 central nervous system metabolic alterations in Alzheimer’s disease. *Alzheimers Res*
924 *Ther*. 2019;11(1):93.
- 925 35. Ciavardelli D, Piras F, Consalvo A, Rossi C, Zucchelli M, Di Ilio C, et al. Medium-chain
926 plasma acylcarnitines, ketone levels, cognition, and gray matter volumes in healthy
927 elderly, mildly cognitively impaired, or Alzheimer’s disease subjects. *Neurobiol Aging*.
928 2016;43:1–12.
- 929 36. Guasch-Ferré M, Ruiz-Canela M, Li J, Zheng Y, Bulló M, Wang DD, et al. Plasma
930 Acylcarnitines and Risk of Type 2 Diabetes in a Mediterranean Population at High
931 Cardiovascular Risk. *J Clin Endocrinol Metab*. 2019;104(5):1508–19.
- 932 37. Mihalik SJ, Goodpaster BH, Kelley DE, Chace DH, Vockley J, Toledo FGS, et al.

- 933 Increased levels of plasma acylcarnitines in obesity and type 2 diabetes and
934 identification of a marker of glucolipototoxicity. *Obesity (Silver Spring)*.
935 2010;18(9):1695–700.
- 936 38. Strand E, Pedersen ER, Svingen GFT, Olsen T, Bjørndal B, Karlsson T, et al. Serum
937 Acylcarnitines and Risk of Cardiovascular Death and Acute Myocardial Infarction in
938 Patients With Stable Angina Pectoris. *J Am Heart Assoc*. 2017 Feb;6(2): e003620.
- 939 39. Topp H, Dörrenhaus A, Bolt H, Schöch G, Föllmann W. Determination of Degradation
940 Rates of Transfer and Ribosomal Ribonucleic Acids in Cultured Rat Hepatocytes by
941 Measuring N⁶-Threoninocarbonyladenine, Dihydrouridine, and Pseudouridine in
942 Medium Using High-Performance Liquid Chromatography. *Anal Biochem*.
943 1997;254(2):200–7.
- 944 40. Nakano K, Nakao T, Schram KH, Hammargren WM, McClure TD, Katz M, et al. Urinary
945 excretion of modified nucleosides as biological marker of RNA turnover in patients
946 with cancer and AIDS. *Clin Chim Acta*. 1993;218(2):169–83.
- 947 41. Zierer J, Kastenmüller G, Suhre K, Gieger C, Codd V, Tsai P-C, et al. Metabolomics
948 profiling reveals novel markers for leukocyte telomere length. *Aging (Albany NY)*.
949 2016;8(1):77–94.
- 950 42. Lieu EL, Nguyen T, Rhyne S, Kim J. Amino acids in cancer. *Exp Mol Med*.
951 2020;52(1):15–30.
- 952 43. Fontecave M, Atta M, Mulliez E. S-adenosylmethionine: nothing goes to waste.
953 *Trends Biochem Sci*. 2004;29(5):243–9.
- 954 44. Gillery P, Jaisson S. Post-translational modification derived products (PTMDPs): toxins
955 in chronic diseases? *Clin Chem Lab Med*. 2014;52(1):33–8.
- 956 45. Boo SH, Kim YK. The emerging role of RNA modifications in the regulation of mRNA

- 957 stability. *Exp Mol Med*. 2020;52(3):400–8.
- 958 46. Zhang X, Trebak F, Souza LAC, Shi J, Zhou T, Kehoe PG, et al. Small RNA modifications
959 in Alzheimer’s disease. *Neurobiol Dis*. 2020;145:105058.
- 960 47. Rhodes CJ, Ghataorhe P, Wharton J, Rue-Albrecht KC, Hadinnapola C, Watson G, et al.
961 Plasma Metabolomics Implicates Modified Transfer RNAs and Altered Bioenergetics
962 in the Outcomes of Pulmonary Arterial Hypertension. *Circulation*. 2017;135(5):460–
963 75.
- 964 48. Sekula P, Del Greco M F, Pattaro C, Köttgen A. Mendelian Randomization as an
965 Approach to Assess Causality Using Observational Data. *J Am Soc Nephrol*.
966 2016;27(11):3253–3265.
- 967 49. Niewczas MA, Mathew A V, Croall S, Byun J, Major M, Sabisetti VS, et al. Circulating
968 Modified Metabolites and a Risk of ESRD in Patients With Type 1 Diabetes and
969 Chronic Kidney Disease. *Diabetes Care*. 2017;40(3):383–90.
- 970 50. Lustgarten MS, Fielding RA. Metabolites Associated With Circulating Interleukin-6 in
971 Older Adults. *J Gerontol A Biol Sci Med Sci*. 2017;72(9):1277–83.
- 972 51. Huang J, Weinstein SJ, Moore SC, Derkach A, Hua X, Liao LM, et al. Serum
973 Metabolomic Profiling of All-Cause Mortality: A Prospective Analysis in the Alpha-
974 Tocopherol, Beta-Carotene Cancer Prevention (ATBC) Study Cohort. *Am J Epidemiol*.
975 2018;187(8):1721–32.
- 976 52. Nierenberg JL, He J, Li C, Gu X, Shi M, Razavi AC, et al. Serum metabolites associate
977 with physical performance among middle-aged adults: Evidence from the Bogalusa
978 Heart Study. *Aging (Albany NY)*. 2020;12(12):11914–41.
- 979 53. Kim GH, Kim JE, Rhie SJ, Yoon S. The Role of Oxidative Stress in Neurodegenerative
980 Diseases. *Exp Neurobiol*. 2015;24(4):325–40.

- 981 54. Schneider N, Hauser J, Oliveira M, Cazaubon E, Mottaz SC, O'Neill B V, et al.
982 Sphingomyelin in Brain and Cognitive Development: Preliminary Data. *eNeuro*.
983 2019;6(4):ENEURO.0421-18.2019.
- 984 55. Olsen ASB, Færgeman NJ. Sphingolipids: membrane microdomains in brain
985 development, function and neurological diseases. *Open Biol*. 2017;7(5):170069.
- 986 56. Montoliu I, Scherer M, Beguelin F, DaSilva L, Mari D, Salvioli S, et al. Serum profiling of
987 healthy aging identifies phospho- and sphingolipid species as markers of human
988 longevity. *Aging (Albany NY)*. 2014;6(1):9–25.
- 989 57. van Echten-Deckert G, Walter J. Sphingolipids: Critical players in Alzheimer's disease.
990 *Prog Lipid Res*. 2012;51(4):378–93.
- 991 58. Engelhart MJ, Geerlings MI, Ruitenbergh A, van Swieten JC, Hofman A, Witteman JCM,
992 et al. Dietary intake of antioxidants and risk of Alzheimer disease. *Jama*.
993 2002;287(24):3223–9.
- 994 59. Pitchumoni SS, Doraiswamy PM. Current Status of Antioxidant Therapy for
995 Alzheimer's Disease. *J Am Geriatr Soc*. 1998;46(12):1566–72.
- 996 60. Rinaldi P, Polidori MC, Metastasio A, Mariani E, Mattioli P, Cherubini A, et al. Plasma
997 antioxidants are similarly depleted in mild cognitive impairment and in Alzheimer's
998 disease. *Neurobiol Aging*. 2003;24(7):915–9.
- 999 61. Burté F, Houghton D, Lowes H, Pyle A, Nesbitt S, Yarnall A, et al. metabolic profiling of
1000 Parkinson's disease and mild cognitive impairment. *Mov Disord*. 2017;32(6):927–32.
- 1001 62. Li L, Sun L, Qiu Y, Zhu W, Hu K, Mao J. Protective Effect of Stachydrine Against
1002 Cerebral Ischemia-Reperfusion Injury by Reducing Inflammation and Apoptosis
1003 Through P65 and JAK2/STAT3 Signaling Pathway. *Frontiers in Pharmacology*. 2020;11.
1004 64.

- 1005 63. Crichton GE, Bryan J, Murphy KJ. Dietary antioxidants, cognitive function and
1006 dementia--a systematic review. *Plant Foods Hum Nutr.* 2013;68(3):279–92.
- 1007 64. Kamat CD, Gadal S, Mhatre M, Williamson KS, Pye QN, Hensley K. Antioxidants in
1008 central nervous system diseases: preclinical promise and translational challenges. *J*
1009 *Alzheimers Dis.* 2008;15(3):473–93.
- 1010 65. Playdon MC, Moore SC, Derkach A, Reedy J, Subar AF, Sampson JN, et al. Identifying
1011 biomarkers of dietary patterns by using metabolomics. *Am J Clin Nutr.* 2016
1012 ;105(2):450–65.
- 1013 66. Krassowski M. ComplexUpset: Create Complex UpSet Plots Using ggplot2
1014 Components. R package Version 0.5.18 [software]. 2020.
- 1015
- 1016

1017 **Supporting Information Captions**

1018

1019 **S1 Table. Full single-metabolite analyses results (models 1-4), including module**

1020 **membership and hub status.**

1021

1022 **S2 Table. Linear regression analyses results for the association of each covariable against**

1023 **each predictor. All analyses are adjusted for sex, age at blood collection and blood**

1024 **collection centre.**

1025

1026 **S3 Table. Pathway analyses results.**

1027

1028 **S4 Table. Module overrepresentation analysis results.**

1029

1030 **S5 Table. Full module analyses results (models 1-4).**

1031

1032 **S6 Table. Linear regression analyses results for the associations between metabolites and**

1033 **outcomes, after adjusting for each covariable individually. All analyses are adjusted for**

1034 **sex, age at blood collection and blood collection centre.**

1035

1036 **S7 Table. Linear regression analyses results for the associations between metabolites and**

1037 **outcomes with and without adjusting for APOE. The maximum N with APOE genotype was**

1038 **used.**

1039

1040 **S8 Table. Linear regression analyses results for the associations between modules and**
1041 **outcomes, after adjusting for each covariable individually.**

1042

1043 **S9 Table. Linear regression analyses results for the associations between modules and**
1044 **outcomes with and without adjusting for APOE. The maximum N with APOE genotype was**
1045 **used.**

1046

1047 **S1 Fig. Flow chart depicting metabolomic data quality control.**

1048

1049 **S2 Fig. Heat map showing trends of associations between the 155 metabolites and**
1050 **cognitive outcomes in models 1-4, organised by metabolite family. Bonferroni-significant**
1051 **metabolites ($p < 1.15 \times 10^{-4}$) are represented by a solid fill, nominal metabolites by a faint fill**
1052 **($p < 0.05$), and non-significant metabolites by no fill ($p > 0.05$).**

1053 *Carb = carbohydrates, Cof & Vit = cofactors & vitamins, En = energy, PCM = partially*

1054 *characterised molecules, Pep = peptides, ACE-III = Addenbrooke's Cognitive Examination-III,*

1055 *DM = delayed memory, STM = short-term memory, PS = processing speed*

1056

1057 **S3 Fig. Scale free topology and mean connectivity plots for weighted gene coexpression**
1058 **network analysis.**

1059

1060 **S1 Methods. Supplementary methods**